More studies are needed to detect the effects of NRTN on non-dopaminergic system in Parkinson’s disease via neural cell adhesion molecule (Sandmark et al., 2018) and syndecam 3 (Bespalov et al., 2011). This evidence concerns the gene CHL1 and Parkinson disease.